biotech
biotech Articles
Plus Therapeutics shares rallied on Tuesday after an FDA update on its treatment of patients with recurrent glioblastoma.
Published:
Three U.S. COVID-19 vaccine trials are now in Phase 3 studies. All three appear to have some serious benefits, but none are approved yet.
Published:
The prize for Nestle in its acquisition of Aimmune Therapeutics is Palforzia, the world’s first treatment for a food allergy.
Published:
Akcea Therapeutics stock jumped on Monday after it was announced that Ionis Pharmaceuticals would be acquiring all of its outstanding shares.
Published:
Fluidigm made a splash with the markets on Wednesday morning after the company announced a critical update from the FDA in regards to its COVID-19 test.
Published:
The August 14 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
Published:
Cancer Genetics shares more than doubled on Monday after the company announced a merger with StemoniX.
Published:
Onconova Therapeutics stock was absolutely crushed to start out the week after the company reported results from its late-stage cancer study.
Published:
Pfizer and BioNTech provided an update for their coronavirus vaccine that is currently in the late stages of development and testing.
Published:
Last Updated:
The FDA has come down on an investigational treatment for moderately to severely active from Gilead Sciences and Galapagos.
Published:
BioMarin Pharmaceutical stock was crushed on Wednesday after an FDA response regarding its valoctocogene roxaparvovec gene therapy for severe hemophilia A.
Published:
Vanda Pharmaceuticals took another big step forward in the fight against COVID-19 on Tuesday morning.
Published:
XBiotech shares made a handy gain on Monday after the company said that it has identified True Human antibodies that could potentially be used as a therapy against SARS-CoV2.
Published:
Unity Biotechnology stock was absolutely crushed on Monday after the company announced results from its midstage study in patients with moderate-to-severe painful osteoarthritis of the knee.
Published:
Principia Biopharma shares jumped to start out the week after it was announced that it would be acquired by Sanofi.
Published: